Zhijun Liu

Title: Innovations of Zhijun Liu in Pharmaceutical Science

Introduction

Zhijun Liu is a prominent inventor based in Beijing, China. He has made significant contributions to the field of pharmaceutical science, particularly in the development of innovative drug formulations. His work focuses on enhancing therapeutic efficacy through novel analogs.

Latest Patents

Zhijun Liu holds a patent for "Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof." This invention provides a GIP analog derived from GIP (1-29, SEQ ID NO: 1), which exhibits both GLP-1 agonist activity and GIPR stimulation activity. The amino acid sequence of the GIP analog is represented by the formula I: Tyr-A2-A3-Gly-Thr-Phe-A7-Ser-Asp-Tyr-Ser-A12-A13-A14-A15-Lys-A17-A18-A19-A20-A21-A22-A23-A24-Trp-Leu-A27-A28-A29-Y. Additionally, the invention includes a pharmaceutical composition comprising the GIP analog and its various uses.

Career Highlights

Zhijun Liu is associated with Beijing Hanmi Pharmaceutical Co., Ltd., where he continues to advance his research and development efforts. His work has been instrumental in creating innovative solutions for diabetes management and related metabolic disorders.

Collaborations

Zhijun Liu collaborates with notable colleagues, including Bo Zhang and Wei Zhang, who contribute to his research initiatives and enhance the scope of his projects.

Conclusion

Zhijun Liu's innovative work in pharmaceutical science exemplifies the impact of research on healthcare solutions. His contributions, particularly in the development of GIP analogs, highlight the importance of innovation in improving therapeutic outcomes.